RxDoctor Payments DataLook up a doctor →

Bruce Lewis, MD

Interventional Cardiology · Maywood, ILNPI 1538238050

Payments from drug & device makers

$1,316,632in general payments, 2019–2025

Across 401 payments — averaging $3283.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$918K
  • Abbott$166K
  • Medtronic$154K
  • Johnson & Johnson$73K
  • Biotronik Inc.$1K
  • Esperion Therapeutics, Inc.$634
  • plus $4K from 24 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$68,99083%
  • Travel & lodging$1,5152%
  • Food & beverage$11,32714%
  • Education$6311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,316,632 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$625,496
Medicare patients
1,549
Services billed
3,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban506$550,279
EliquisApixaban447$488,176
Repatha SureclickEvolocumab261$217,750
JardianceEmpagliflozin188$194,967
EntrestoSacubitril/Valsartan126$155,152
MultaqDronedarone Hcl42$73,167
FarxigaDapagliflozin Propanediol60$56,688
Praluent PenAlirocumab39$48,830
OzempicSemaglutide12$24,039
BrilintaTicagrelor13$17,144
Metoprolol Succinate970$15,748
Atorvastatin Calcium1,317$13,876
ClopidogrelClopidogrel Bisulfate970$13,463
Sildenafil Citrate14$13,405
NexlizetBempedoic Acid/Ezetimibe13$9,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$72,561$550,279506 claims
NovartisEntresto$510$155,152126 claims
AstraZenecaFarxiga, Brilinta$157$73,83273 claims
Esperion Therapeutics, Inc.Nexlizet$634$9,48213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →